Kobayashi Pharmaceutical Co., Ltd.
Notice of Change in Consolidated Subsidiaries Due to Share Transfer
Transfer of all shares of Jiangsu Kobayashi Pharmaceutical Co., Ltd. to Wantianwan Techan Pharmaceutical (Xiamen) Co., Ltd. The share ownership before and after transfer will be 100% → 0%, with the closing date planned for the end of October 2026. There is a possibility of recognizing extraordinary losses in the fiscal year ending December 2026.
Key Figures
- Transfer shareholding ratio: 100% → 0%
- Transfer destination capital: 178 million yuan
- Recognition of extraordinary losses: FY2026 (undetermined)
AI要約
Overview of the transfer
Kobayashi Pharmaceutical decided by board resolution to transfer all shares of its consolidated subsidiary Jiangsu Kobayashi Pharmaceutical Co., Ltd. to Wantianwan Techan Pharmaceutical (Xiamen) Co., Ltd., with no remaining capital or personnel relationships after the transfer. The transfer agreement is scheduled to be signed in mid-August 2026, with the closing date planned for the end of October 2026.
Future financial impact and disclosure plan
As a result of the transfer, we expect to recognize extraordinary losses in the fiscal year ending December 2026, though the amount is currently under review. We will promptly disclose any new information as it becomes available. Also, the Japanese brand name An-meltsu (安美露) is not manufactured by Jiangsu Kobayashi Pharmaceutical, and the transfer does not affect it.
Kobayashi Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
